Given the pronounced upregulation of SAE2 and sumoylated proteins in MCL and their necessity for MCL cell survival, we next wanted to know if targeting SAE2 with a clinical grade small molecule inhibitor would lead to anti-tumor activity in MCL. The gene discussed is UBA2; the disease is mantle cell lymphoma.